LEGN Relative Valuation
LEGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LEGN is overvalued; if below, it's undervalued.
Historical Valuation
Legend Biotech Corp (LEGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.87 is considered Undervalued compared with the five-year average of -26.12. The fair price of Legend Biotech Corp (LEGN) is between 462.21 to 738.13 according to relative valuation methord. Compared to the current price of 22.72 USD , Legend Biotech Corp is Undervalued By 95.08%.
Relative Value
Fair Zone
462.21-738.13
Current Price：22.72
95.08%
Undervalued
-82.67
PE
1Y
3Y
5Y
28.96
EV/EBITDA
Legend Biotech Corp. (LEGN) has a current EV/EBITDA of 28.96. The 5-year average EV/EBITDA is -17.93. The thresholds are as follows: Strongly Undervalued below -74.89, Undervalued between -74.89 and -46.41, Fairly Valued between 10.56 and -46.41, Overvalued between 10.56 and 39.04, and Strongly Overvalued above 39.04. The current Forward EV/EBITDA of 28.96 falls within the Overvalued range.
-60.44
EV/EBIT
Legend Biotech Corp. (LEGN) has a current EV/EBIT of -60.44. The 5-year average EV/EBIT is -10.22. The thresholds are as follows: Strongly Undervalued below -116.64, Undervalued between -116.64 and -63.43, Fairly Valued between 42.99 and -63.43, Overvalued between 42.99 and 96.20, and Strongly Overvalued above 96.20. The current Forward EV/EBIT of -60.44 falls within the Historic Trend Line -Fairly Valued range.
2.87
PS
Legend Biotech Corp. (LEGN) has a current PS of 2.87. The 5-year average PS is 28.04. The thresholds are as follows: Strongly Undervalued below -15.45, Undervalued between -15.45 and 6.30, Fairly Valued between 49.79 and 6.30, Overvalued between 49.79 and 71.53, and Strongly Overvalued above 71.53. The current Forward PS of 2.87 falls within the Undervalued range.
89.37
P/OCF
Legend Biotech Corp. (LEGN) has a current P/OCF of 89.37. The 5-year average P/OCF is -24.05. The thresholds are as follows: Strongly Undervalued below -121.49, Undervalued between -121.49 and -72.77, Fairly Valued between 24.67 and -72.77, Overvalued between 24.67 and 73.39, and Strongly Overvalued above 73.39. The current Forward P/OCF of 89.37 falls within the Strongly Overvalued range.
28.54
P/FCF
Legend Biotech Corp. (LEGN) has a current P/FCF of 28.54. The 5-year average P/FCF is 27.19. The thresholds are as follows: Strongly Undervalued below -373.22, Undervalued between -373.22 and -173.02, Fairly Valued between 227.39 and -173.02, Overvalued between 227.39 and 427.59, and Strongly Overvalued above 427.59. The current Forward P/FCF of 28.54 falls within the Historic Trend Line -Fairly Valued range.
Legend Biotech Corp (LEGN) has a current Price-to-Book (P/B) ratio of 3.93. Compared to its 3-year average P/B ratio of 8.28 , the current P/B ratio is approximately -52.56% higher. Relative to its 5-year average P/B ratio of 10.66, the current P/B ratio is about -63.14% higher. Legend Biotech Corp (LEGN) has a Forward Free Cash Flow (FCF) yield of approximately -4.75%. Compared to its 3-year average FCF yield of -3.07%, the current FCF yield is approximately 54.81% lower. Relative to its 5-year average FCF yield of -3.56% , the current FCF yield is about 33.28% lower.
3.93
P/B
Median3y
8.28
Median5y
10.66
-4.75
FCF Yield
Median3y
-3.07
Median5y
-3.56
Competitors Valuation Multiple
The average P/S ratio for LEGN's competitors is 231.52, providing a benchmark for relative valuation. Legend Biotech Corp Corp (LEGN) exhibits a P/S ratio of 2.87, which is -98.76% above the industry average. Given its robust revenue growth of 69.99%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LEGN decreased by 40.37% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 160.21M to 272.33M.
The secondary factor is the P/E Change, contributed -28.98%to the performance.
Overall, the performance of LEGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
Frequently Asked Questions
Is Legend Biotech Corp (LEGN) currently overvalued or undervalued?
Legend Biotech Corp (LEGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.87 is considered Undervalued compared with the five-year average of -26.12. The fair price of Legend Biotech Corp (LEGN) is between 462.21 to 738.13 according to relative valuation methord. Compared to the current price of 22.72 USD , Legend Biotech Corp is Undervalued By 95.08% .
What is Legend Biotech Corp (LEGN) fair value?
LEGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Legend Biotech Corp (LEGN) is between 462.21 to 738.13 according to relative valuation methord.
How does LEGN's valuation metrics compare to the industry average?
The average P/S ratio for LEGN's competitors is 231.52, providing a benchmark for relative valuation. Legend Biotech Corp Corp (LEGN) exhibits a P/S ratio of 2.87, which is -98.76% above the industry average. Given its robust revenue growth of 69.99%, this premium appears sustainable.
What is the current P/B ratio for Legend Biotech Corp (LEGN) as of Jan 09 2026?
As of Jan 09 2026, Legend Biotech Corp (LEGN) has a P/B ratio of 3.93. This indicates that the market values LEGN at 3.93 times its book value.
What is the current FCF Yield for Legend Biotech Corp (LEGN) as of Jan 09 2026?
As of Jan 09 2026, Legend Biotech Corp (LEGN) has a FCF Yield of -4.75%. This means that for every dollar of Legend Biotech Corp’s market capitalization, the company generates -4.75 cents in free cash flow.
What is the current Forward P/E ratio for Legend Biotech Corp (LEGN) as of Jan 09 2026?
As of Jan 09 2026, Legend Biotech Corp (LEGN) has a Forward P/E ratio of -82.67. This means the market is willing to pay $-82.67 for every dollar of Legend Biotech Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Legend Biotech Corp (LEGN) as of Jan 09 2026?
As of Jan 09 2026, Legend Biotech Corp (LEGN) has a Forward P/S ratio of 2.87. This means the market is valuing LEGN at $2.87 for every dollar of expected revenue over the next 12 months.